WEBULL

Vitrolife (OM:VITR) Stock Faces Recovery Questions As Q2 Profit Contrasts 4.98b TTM Loss

Simply Wall St · 1d ago

Vitrolife (OM:VITR) has reported Q2 2026 revenue of SEK857 million with EPS of SEK0.95, while the trailing twelve months still show a loss of SEK4.98 billion and EPS of SEK36.80 in the red. The company has seen quarterly revenue move from SEK871 million in Q2 2025 to SEK892 million in Q4 2025 and SEK807 million in Q1 2026, with EPS shifting from SEK0.74 to a loss of SEK39.23 and then back to SEK0.75 and SEK0.95 most recently. This gives investors a mixed picture of earnings power around relatively steady sales. Overall, Vitrolife enters this earnings season with revenue holding up but profitability and margins still under pressure, which is central to how the results will be read.

See our full analysis for Vitrolife.

With the latest numbers on the table, the next step is to see how Vitrolife's reported revenue, losses, and margin pressure line up with the dominant market narratives and where those stories might need to be refreshed.

See what the community is saying about Vitrolife

OM:VITR Revenue & Expenses Breakdown as at Jul 2026
OM:VITR Revenue & Expenses Breakdown as at Jul 2026

TTM loss of SEK4.98b despite steady quarterly profits

  • Over the last twelve months, Vitrolife reported total revenue of SEK3.39b and a net loss of SEK4.98b, even though the last four individual quarters, except Q4 2025, mostly show positive net income between SEK100 million and SEK129 million.
  • Bulls point to the recent quarterly profits as early support for a recovery story, yet they are working against a very large trailing loss:
    • Optimistic forecasts cited for Vitrolife expect earnings to move from a loss of about SEK5.0b today to SEK1.1b by around 2029. However, the current twelve month loss and the extreme Q4 2025 loss of SEK5.31b both highlight how far the company still has to go.
    • This tension means the bullish case leans heavily on the idea that the more recent run of SEK100 million plus quarterly profits is a better guide to the future than the deep trailing loss embedded in the last year.
Over the last year, bulls argue that these recent profitable quarters mark a turning point for Vitrolife, but the scale of the SEK4.98b loss keeps the recovery debate very much alive for long term holders. 🐂 Vitrolife Bull Case

Current losses vs SEK190.53 DCF fair value

  • The data shows Vitrolife is unprofitable on a trailing basis, with losses having widened at about 51% per year over five years. At the same time, the current share price of SEK92.30 is indicated as about 51.6% below a DCF fair value of SEK190.53.
  • Skeptics question whether that valuation gap can close while earnings are still in the red:
    • The bearish narrative flags that margins are currently described as deeply negative in the model, even though quarterly net income has recently been around SEK100 million, so the DCF fair value assumes a sharp inflection from today’s weak five year earnings track record.
    • In addition, a P/S of 3.7x versus peer and industry averages of 20.3x and 9.1x suggests the low multiple is tied to those historical losses, which bears see as a sign that the market is still pricing in meaningful risk around the path back to sustained profitability.
For cautious investors, the mix of a wide DCF fair value gap and a history of widening losses is exactly what keeps the bearish case in focus. 🐻 Vitrolife Bear Case

6.5% revenue growth but profit quality in question

  • Vitrolife’s revenue growth is reported at about 6.5% per year over the last twelve months, roughly matching the wider Swedish market, while trailing net profit margins remain negative with no improvement flagged despite several quarters of SEK100 million plus quarterly earnings.
  • Consensus narrative supporters see steady revenue and product adoption as a base for margin repair, but the figures highlight a mixed picture:
    • On the supportive side, quarterly revenue has hovered between SEK807 million and SEK892 million from Q2 2025 through Q2 2026, which is consistent with the idea of a resilient top line that could potentially support better margins if costs are contained.
    • On the challenging side, the trailing EPS figure sits at a loss of SEK36.80 per share and past losses have reportedly grown about 51% per year, which sits awkwardly beside expectations that margins will turn positive to above 30% within a few years.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Vitrolife on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this Vitrolife update leaves you weighing both upside and risk, now is the moment to review the figures yourself and stress test the story. To see what is currently driving optimism, take a closer look at the 2 key rewards.

See What Else Is Out There

Vitrolife shows resilient revenue but carries a SEK4.98b trailing loss, deeply negative margins, volatile quarterly earnings and a history of widening losses that may concern cautious investors.

If those swings in profitability and deep losses feel uncomfortable, you may want to shift your focus toward companies with steadier metrics by checking out 286 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.